Original Article

Comparison of Nonesophageal Eosinophilic Gastrointestinal Disorders with Eosinophilic Esophagitis: A Nationwide Survey



Mayu Yamamoto, MD^a, Saori Nagashima, MD^a, Yoshiyuki Yamada, MD, PhD^b, Takatsugu Murakoshi, MD, PhD^c, Yasuyuki Shimoyama, MD, PhD^d, Sakuma Takahashi, MD, PhD^e, Hideyuki Seki, MD, PhD^f, Takashi Kobayashi, MD, PhD^g, Yuichi Hara, MD^h, Hiromi Tadaki, MD, PhDⁱ, Norihisa Ishimura, MD, PhD^j, Shunji Ishihara, MD, PhD^j, Yoshikazu Kinoshita, MD, PhD^{j,k}, Hideaki Morita, MD, PhD^l, Yukihiro Ohya, MD, PhD^m, Hirohisa Saito, MD, PhD^l, Kenji Matsumoto, MD, PhD^j, and Ichiro Nomura, MD, PhD^{a,m} Tokyo, Gunma, Kagawa, Hokkaido, Aichi, Fukuoka, Kanagawa, Shimane, and Himeji, Japan

What is already known about this topic? Unlike for eosinophilic esophagitis (EoE), the prevalence, putative phenotypes, and natural courses of non-esophageal eosinophilic gastrointestinal disorders (non-EoE EGIDs) remain poorly understood.

What does this article add to our knowledge? Continuous type was 64% (95% confidence interval [CI]: 55-72) in non-EoE EGIDs and 66% (95% CI: 58-74) in EoE. Restriction of activity, weight loss, surgery, and hypoproteinemia in non-EoE EGIDs were more frequent in pediatric patients than adult patients.

How does this study impact current management guidelines? Most non-EoE EGIDs were persistent and severe, especially in children. These findings will promote development of treatment strategies that do not inhibit growth and have fewer long-term side effects.

BACKGROUND: Eosinophilic esophagitis (EoE) has increased rapidly and has been well characterized. However, no nationwide survey has been conducted regarding non-esophageal eosinophilic gastrointestinal disorders (non-EoE EGIDs), and they remain poorly understood.

OBJECTIVE: To compare the clinical features and natural histories of non-EoE EGIDs and EoE by using the same questionnaire, for all ages.

METHODS: We conducted a nationwide hospital-based survey of patients who visited hospitals from January 2013 through December 2017. We randomly selected 10,000 hospitals that perform endoscopy. We analyzed the demographics, symptoms, gastrointestinal histology, treatments, and natural histories of EoE and non-EoE EGIDs.

RESULTS: A total of 2906 hospitals responded to the questionnaire. We identified 1542 patients and obtained detailed data for 786 patients, consisting of 39% EoE and 61% non-EoE EGIDs. The clinical characteristics were analyzed for patients who met the "definite" criteria that excluded comorbidities. Non-EoE EGIDs showed no gender difference, whereas EoE was malepredominant. Tissue eosinophilia was often seen in the small intestine (62%) and stomach (49%). The frequency of

Available online June 29, 2021.

^aDivision of Eosinophilic Gastrointestinal Disorders, National Research Institute for Child Health and Development, Tokyo, Japan

^bDivision of Allergy and Immunology, Gunma Children's Medical Center, Gunma, Japan

^cDepartment of Gastroenterology, Tokyo Metropolitan Children's Medical Center, Tokyo, Japan

^dDepartment of Gastroenterology and Hepatology, Gunma University Graduate School of Medicine, Gunma, Japan

^eDepartment of Gastroenterology, Kagawa Prefectural Central Hospital, Kagawa, Japan

^fDepartment of Gastroenterology, KKR Sapporo Medical Center, Hokkaido, Japan

^gDepartment of Gastroenterology, Fujita Health University Bantane Hospital, Aichi, Japan

^hDepartment of Gastroenterology, Fukuoka Sanno Hospital, Fukuoka, Japan

Department of Pediatrics, National Hospital Organization Yokohama Medical Center, Kanagawa, Japan

^jDepartment of Gastroenterology, Shimane University Hospital, Shimane, Japan ^kDepartment of Medicine, Steel Memorial Hirohata Hospital, Himeji, Japan

Department of Allergy and Clinical Immunology, National Research Institute for Child Health and Development, Tokyo, Japan

^mAllergy Center, National Center for Child Health and Development, Tokyo, Japan

This work was supported by Health, Labor and Welfare Sciences Research Grants for Research on Policy Planning and Evaluation for Rare and Intractable Diseases, from the Ministry of Health, Labour and Welfare, Japan, Grant/Award Numbers: 201610015B, 201811052A (to I. Nomura).

Conflicts of interest: The authors declare that they have no relevant conflicts of interest.

Received for publication December 9, 2020; revised June 8, 2021; accepted for publication June 10, 2021.

Corresponding authors: Ichiro Nomura, MD, PhD, Division of Eosinophilic Gastrointestinal Disorders, National Research Institute for Child Health and Development, 2-10-1, Okura, Setagaya-ku, Tokyo 157-8535, Japan. E-mail: nomura-i@ncchd.go.jp; or: Kenji Matsumoto, MD, PhD, Department of Allergy and Clinical Immunology, National Research Institute for Child Health and Development, 2-10-1, Okura, Setagaya-ku, Tokyo 157-8535, Japan. E-mail: matsumoto-k@ncchd.go.jp.

²²¹³⁻²¹⁹⁸

^{© 2021} American Academy of Allergy, Asthma & Immunology

https://doi.org/10.1016/j.jaip.2021.06.026